Squarepoint’s Centessa Pharmaceuticals CNTA Stock Holding History

Squarepoint’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.01M	Sell	50,606 -31,206	-38%	-$798K	﹤0.01%	2181
2025 Q4	$2.05M	Buy	81,812 +62,399	+321%	+$1.58M	﹤0.01%	2046
2025 Q3	$471K	Sell	19,413 -20,347	-51%	-$362K	﹤0.01%	3292
2025 Q2	$522K	Sell	39,760 -3,102	-7%	-$39.3K	﹤0.01%	3242
2025 Q1	$616K	Buy	42,862 +16,056	+60%	+$263K	﹤0.01%	3103
2024 Q4	$449K	Buy	26,806 +6,685	+33%	+$111K	﹤0.01%	3815
2024 Q3	$322K	Buy	+20,121	New	+$246K	﹤0.01%	3396
2021 Q3	–	Sell	-37,771	Closed	-$839K	–	2975
2021 Q2	$839K	Buy	+37,771	New	+$888K	﹤0.01%	1765

Other funds holding CNTA

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

IVLAV

Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Squarepoint's CNTA Position: Q1 2026 in Review

Squarepoint reduced its Centessa Pharmaceuticals (CNTA) stake by 38% in Q1 2026, selling an estimated $798K and leaving 50,606 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

Squarepoint first reported a position in CNTA in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.05M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

Squarepoint held 50,606 shares of Centessa Pharmaceuticals worth $2.01M as of Q1 2026.
Squarepoint sold 31,206 Centessa Pharmaceuticals shares in Q1 2026, an estimated $798K.
Centessa Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2181 holding.
Squarepoint first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
Squarepoint's Centessa Pharmaceuticals position peaked at $2.05M in Q4 2025.
161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.